CytRx Corporation Subsidiary Centurion BioPharma Announces Conclusion Of Pre-Clinical Phase For Its Albumin Binding Ultra High Potency LADR Drug Candidates And Accompanying Companion Diagnostic
Benzinga Newsdesk